Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... The company also announced its first-ever dividend and authorized another $3 ...

Regeneron is now a dividend-paying company. The stock has lagged the market over the last year, and that remains true after the post-earnings rise. It takes years to build a reputation as a strong ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average rating of “Moderate Buy” from the ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech company's business remains solid. Regeneron's share repurchase program ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.